Dr. Heather F. Pidcoke joins Cellphire, Inc. as Chief Medical Officer

March 1, 2018 -- Cellphire, Inc., the global leader in long-term stabilization and storage of platelets and other cells, announced today that Heather Pidcoke, MD, MSCI, Ph.D., has joined the company as Chief Medical Officer. Dr. Pidcoke’s translational research interests include trauma critical care and novel transfusion products aimed at improving the resuscitation of massively bleeding patients.

Prior to joining Cellphire, Dr. Pidcoke was Director, Global Translational Affairs at Terumo BCT where she was the Principal Investigator for four major product development efforts.  Previously, she served as the Deputy Task Area Manager and Research Physiologist in the Coagulation and Blood Research program (CBR) at the U.S. Army Institute of Surgical Research (USAISR) and as Adjunct Professor in the Department of Surgery at the University of Texas, Health Science Center, San Antonio. Dr. Pidcoke was awarded a U.S. Army Commander’s Award for Civilian Service in recognition of her contributions in advancing medical research for military personnel, and the Presidential Early Career Award for Scientists and Engineers. 

She received a Doctor of Medicine degree from the Keck School of Medicine of the University of Southern California and a Ph.D. (Physiology) from the Graduate School of Biomedical Sciences at the University of Texas Health Science Center. 

“We are very excited to have Dr. Pidcoke join Cellphire”, said G. Michael Fitzpatrick, President and Director of R&D. “Her experience and expertise will allow us to move Thrombosomes and other developmental projects into the physician’s hands sooner and revolutionize blood support in the 21st century.” 

# # #

 About Cellphire, Inc. 

Cellphire, Inc., based in Rockville, Maryland, is the only U.S. company developing freeze-dried platelet products. Cellphire is focused on applying its cellular stabilization technology to all cell types in order to provide lifesaving products where none are routinely available. Platelets are critical to the body’s vascular system and responsible for the body’s ability to stop bleeding. Unlike other blood products that can be frozen and stockpiled for use when needed, platelet products currently used can only be stored for 5-7 days. Cellphire’s lead product, Thrombosomes®, a human platelet derived hemostatic agent, uses a proprietary technology to freeze-dry platelets into a product that can be stored for years, then reconstituted with sterilized water. Cellphire’s platform technology has potential applications across a wide range of cell types and medical applications from trauma to wound care, imaging, targeted drug delivery and regenerative medicine.  This project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201300021C.  For more information, please view www.cellphire.com.

Cautionary Note Regarding Forward-Looking Statements  

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipated”, “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Cellphire’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, increased regulatory requirements, Cellphire’s reliance on third parties over which it may not always have full control, and others. Any forward-looking statements speak only as of the date of this press release and are based on information available to Cellphire as of the date of this release, and Cellphire assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.


Thomas Dann
(240) 268-2489

Source:  Cellphire, Inc.